Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives as Dipeptidyl Peptidase 4 Inhibitors

被引:1
作者
Liu, Yang [1 ]
Jiang, Chaoyi [1 ]
Wu, Haoshu [2 ]
Wu, Peng [1 ]
Si, Meimei [2 ]
Hu, Yongzhou [1 ]
Liu, Tao [1 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, ENS Joint Lab Med Chem, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmacol & Toxicol, Hangzhou 310058, Zhejiang, Peoples R China
关键词
Diabetes; docking; DPP-4; inhibitors; drug design; imidazolone; synthesis; IV INHIBITORS; MEDICINAL CHEMISTRY; POTENT;
D O I
10.2174/1573406411309070007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of novel imidazolone derivatives were designed and synthesized via a rational drug design strategy. These compounds were obtained from 3-substituted imidazolidine-2,4-dione through alkylation, formylation, dehydration, and amination. The structures were characterized by H-1 NMR, C-13 NMR, and MS. All target compounds were screened for their DPP-4 inhibitory activity in vitro. The results revealed that some imidazolone derivatives showed potent DPP-4 inhibition. Compound 5b had an IC50 value of 2.21 mu M inhibitory activity against DPP-4. As a promising lead compound, compound 5b with DPP-4 binding mode was further studied by docking analysis. The expected interaction mode was obtained.
引用
收藏
页码:938 / 946
页数:9
相关论文
共 16 条
  • [1] Ba LA, 2007, ARKIVOC, P374
  • [2] Inhibitors of dipeptidyl peptidase IV:: a novel approach for the prevention and treatment of Type 2 diabetes?
    Deacon, CF
    Ahrén, B
    Holst, JJ
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) : 1091 - 1102
  • [3] Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
    Deacon, CF
    Hughes, TE
    Holst, JJ
    [J]. DIABETES, 1998, 47 (05) : 764 - 769
  • [4] Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
    Feng, Jun
    Zhang, Zhiyuan
    Wallace, Michael B.
    Stafford, Jeffrey A.
    Kaldor, Stephen W.
    Kassel, Daniel B.
    Navre, Marc
    Shi, Lihong
    Skene, Robert J.
    Asakawa, Tomoko
    Takeuchi, Koji
    Xu, Rongda
    Webb, David R.
    Gwaltney, Stephen L., II
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (10) : 2297 - 2300
  • [5] Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy
    Gallwitz, Baptist
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (06) : 723 - 732
  • [6] Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes
    Gupta, Rajesh
    Walunj, Sameer S.
    Tokala, Ranjeet K.
    Parsa, Kishore V. L.
    Singh, Santosh Kumar
    Pal, Manojit
    [J]. CURRENT DRUG TARGETS, 2009, 10 (01) : 71 - 87
  • [7] Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
    Havale, Shrikanth H.
    Pal, Manojit
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (05) : 1783 - 1802
  • [8] Hu Y.Z., 2010, C.N. Patent, Patent No. [101,875,636, 101875636]
  • [9] The glucagon-like peptides
    Kieffer, TJ
    Habener, JL
    [J]. ENDOCRINE REVIEWS, 1999, 20 (06) : 876 - 913
  • [10] Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration
    Kondo, Takashi
    Nekado, Takahiro
    Sugimoto, Isamu
    Ochi, Kenya
    Takai, Shigeyuki
    Kinoshita, Atsushi
    Tajima, Yohei
    Yamamoto, Susumu
    Kawabata, Kazuhito
    Nakai, Hisao
    Toda, Masaaki
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (07) : 2631 - 2650